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Hepatocellular carcinoma (HCC) is the most common primary liver malignancy.The associ-
ation of HCC with chronic liver disease (CLD) is well known and making treatment complex
and challenging. The treatment of HCC must take into consideration, the severity of CLD,
the stage of HCC, and the clinical condition of the patient. Liver resection (LR) is one of
the most efficient treatments for patients with HCC. Better liver function assessment,
increased understanding of segmental liver anatomy using more accurate imaging stud-
ies, and surgical technical progress are the important factors that have led to reduced
mortality, with an expected 5 year survival of 38–61% depending on the stage of the dis-
ease. However, the procedure is applicable to <30% of all HCC patients, and 80% of the
patients after LR recurred within 5 years.There are recent advances and prospects in LR for
HCC in several aspects. Three-dimensional computed tomography imaging assisted pre-
operative surgical planning facilitates unconventional types of LR. Emerging evidences of
laparoscopic hepatectomy and prospects for the use of newly developing chemotherapies
as a combined therapy may lead to expanding indication of LR. LR and liver transplanta-
tion could be associated rather than considered separately with the current concepts of
“bridging LR” and “salvage transplantation.”
Keywords: hepatocellular carcinoma, liver resection, laparoscopic hepatectomy, chemotherapy, 3-dimensional
computed tomography
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common can-
cer and the most common primary liver malignancy (1). The
association of HCC with chronic liver disease (CLD), due to
viral infection, alcohol consumption, metabolic syndrome, etc., is
well known and making treatment complex and challenging. The
underlying liver parenchyma displays various histological changes,
including steatosis, inflammation, and fibrosis to cirrhosis. These
histological changes of the underlying parenchyma and the risk
of multicentric carcinogenesis from chronically injured liver tis-
sue limit the possibility of curative treatments, which include local
ablation of small size and number tumors, liver resection (LR),
and liver transplantation (LT) (2).
Liver resection is one of the most efficient treatments for HCC
patients (3, 4). Considerable progress observed during the last
10 years in screening, treatment of the underlying liver disease,
early radiological diagnosis, and surgical techniques has updated
the indications for LR (2). Better liver function assessment, under-
standing of segmental liver anatomy using more accurate imaging
studies, and surgical technical progress are the most important
factors that have led to reduced mortality, with an expected 5-
year survival of 38–61% depending on the stage of the disease
(5). However, only <30% of patients with HCC are eligible for
surgery (3, 4). Emerging evidences of laparoscopic hepatectomy
and prospects for the use of newly developing chemotherapies as a
combined therapy may lead to expanding indication of LR (6, 7).
In this review, we present recent advances in LR of HCC.
CURRENT CONCEPT OF LIVER RESECTION FOR
HEPATOCELLULAR CARCINOMA
The largest report of LR for HCC is from the Liver Cancer Study
Group in Japan, which has reported 1-, 3-, 5-, and 10-year sur-
vival rates of 85, 64, 45, and 21%, respectively, in 6,785 cirrhotic
patients treated by LR between 1988 and 1999 (8). Comparable
results have been reported by other groups worldwide without
differences between Western and Eastern countries. Survival rates
as high as 60% at 5 years could have been achieved in Child-Pugh
A patients with well-encapsulated tumors of ≤2 cm in diameter.
Results from patients with good liver function and anatomical LR
according to the architecture of the portal vein (although<10% of
all patients) could be favorably compared with those from patients
with LT.
There are several reports describing that anatomical LR for
small solitary HCC achieve significantly better overall and disease-
free survival than limited resections, without increasing the post-
operative risk (9, 10). Intrahepatic metastasis of HCC along the
portal vein and the presence of satellite nodules within 2 cm from
the main nodule (11) are the basis of the concept for anatomi-
cal LR, complete removal of the tumor-bearing portal territory.
Anatomical LR has the potential to remove undetected cancerous
foci (portal vein metastases and satellite nodules) disseminated
from the main tumor and is recommended in many reports if
possible.
In patients with HCC, both tumor extension and severity of
liver dysfunction influence the indication and extent of LR. When
www.frontiersin.org June 2014 | Volume 1 | Article 21 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morise et al. Liver resection for hepatocellular carcinoma
considering the treatment of HCC in patients with CLD, the degree
of invasive surgical stress, especially to the impaired liver, should
be considered in addition to the oncological therapeutic effects.
Patients with severe CLD have various (overt and preliminary)
symptoms, such as (1) deteriorations of protein synthesis and
metabolism; (2) GI tract congestion, ascites, and pancytopenia due
to portal hypertension and hypersplenism; and (3) susceptibility
to infectious diseases and hepatopulmonary syndrome (hypox-
emia) due to increased shunt vessels (12). Cirrhotic patients have
high morbidity and mortality following anesthesia and surgery
(13), and the risk of abdominal operations increases according
to the preoperative Child-Pugh classification (14) of the patients
(15). Major histological changes observed in patients with HCC
include fibrosis ranging from mild (F1) to cirrhosis (F4). Latter
stages of cirrhosis also have a lower rate of regeneration after LR,
more frequent association with portal hypertension, and higher
risk of tumor multiplicity/recurrence (16, 17). Steatosis and the
inflammatory process also have a significant influence on the
course after LR, even absence of extensive fibrosis. LR in diseased
parenchyma presents operative risk due to altered texture of the
liver parenchyma, impaired liver regeneration, and deteriorated
liver function leading to coagulation defects, an increased risk of
infection, etc. (18). There is a close relationship between the extent
of resected liver volume and post-operative morbidity/mortality
of LR in patients with CLD. The fact limits the indication of LR
for large tumors or small but centrally located tumors (19). The
most difficult point of LR in patients with HCC and CLD is that it
should be curative with the resection of the tumor vascular territo-
ries and also preserve as much liver volume as possible to prevent
post-operative liver failure.
ASSESSMENT AND MODULATION OF REMNANT LIVER
FUNCTION
Small remnant liver volume is associated with poor post-operative
liver function and a high mortality/morbidity after LR (20).
Although the safety limit for the remnant liver volume in patients
with normal liver is approximately 30% of the total liver volume
(TLV), it is generally thought that a remnant liver volume of 40–
50% should be preserved after major LR in patients with CLD.
The liver is characterized by its capacity to ensure apparent nor-
mal liver function with a reduced functional volume and its ability
to regenerate. However, the ability to regeneration varies depend-
ing on factors such as fibrosis of remnant liver, portal flow, etc.
Thus, adequate volume of future liver remnant (FLR) should be
different in each individual patient. Although the aim of preop-
erative assessment of liver function is to prevent post-operative
liver failure in each individual patient, the assessments for the
post-operative functionality of a reduced-volume FLR and its
capacity to regenerate is difficult. Because there are no valuable
stress tests to assess the potential of liver function, preoperative
assessment in patients with CLD involves joint interpretation of
several biological, morphological, histological, and hemodynamic
factors.
One widely used method of biological assessment is the
Child-Pugh classification (11), which was originally designed for
predicting the prognosis of patients with portal hypertension
undergoing shunting operations. Resection is contraindicated in
grade C cirrhotic patients and restricted to very limited resection
in grade B cirrhotic patients (21). However, even in grade A cir-
rhotic patients with apparently normal liver function, the risk of
liver surgery is increased, necessitating the development of more
sophisticated quantitative liver function tests. Among the various
methods available, the indocyanine green (ICG) clearance rate
represents the most common test for predicting mortality after
hepatectomy (22, 23). The normal ICG value in healthy patients
is approximately 10%, and cutoff values predictive of safe major
hepatectomies range from 14 to 17% (24, 25). Minor resections can
be performed for values up to 22% (26), limited hepatectomies for
values up to 40% (19), and limited wedge laparoscopic resections,
in the opinion of some researchers, can be tolerated for even higher
values (27, 28). The model for end-stage liver disease (MELD)
score was validated as an accurate predictor of survival among
different populations of patients with advanced liver disease (29,
30). In the case of LR, the impact of the MELD score was studied
only retrospectively in some series of cirrhotic patients, who had
undergone LR for HCC. In two series of cirrhotic patients who
underwent LR for HCC, the authors showed that a MELD score
>8 was associated with a higher risk of mortality, morbidity, and
impaired long-term survival (29, 30).
Preoperative portal vein embolization (PVE) was first intro-
duced by Makuuchi et al. (28) and widely recognized as an effective
method for preoperative volume modulation for small FLR. How-
ever, the degree of hypertrophy of the FLR after PVE is variable
in patients with CLD (20, 31). It is generally accepted that the
absence of early hypertrophy of a non-embolized liver follow-
ing technically successful PVE is an indicator of low regenerative
capacity that would contraindicate LR, and thus, the response rep-
resents a real dynamic stress test before major LR (32). It has been
shown that sequential selective transarterial chemoembolization
(TACE) before PVE increases the rate of hypertrophy (32, 33). In
the event of inadequate FLR hypertrophy that precludes LR, this
combined vascular obstruction of the tumor territory represents
an efficient treatment of HCC. As other means of anticipating
post-operative liver failure, there are several reports using the vol-
umetry data from computed tomography (CT) for the evaluations
of the FLR volume in the proportion of body weight, body surface
area, and TLV (34, 35), the hypertrophy rate of the FLR/TLV ratio
(36), etc.
ANATOMICAL RESECTION AND IMAGING
The anatomical territory of HCC ranges from subsegment to lobe
according to the size and location of the tumor. Anatomical resec-
tions of small solitary HCCs achieve significantly better overall and
disease-free survival than do limited resections, without increasing
the post-operative risk (9, 10). However, the benefit of segmental
resection may only become apparent in tumors between 2 and
5 cm. For the tumors <2 cm in size, the risk of dissemination is
considered to be negligible with equivalent efficacy of local abla-
tive therapy; for the tumors more than 5 cm, majority of patients
will already have macroscopic vascular invasion or satellite nodules
that lead to a high incidence of recurrence (37). In the case of cen-
tral tumors with undefined vascular territory, some authors have
found lower recurrence rates and greater survival with 2-cm surgi-
cal margins compared with 1-cm margins (38), and other authors
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have found no difference between margins <1 or >1 cm (39, 40).
The adequate margin of LR should also depend on the tumor
type (with/without capsules, with/without invasion outside the
capsule, etc.) and still under discussion. Three-dimensional CT-
assisted preoperative surgical planning allows determination of
resectability and changes in operative strategy (resection modifi-
cations/extensions/intrahepatic vascular reconstructions studying
portal distribution, hepatic vein anatomy for adequate venous
drainage, biliary distribution for avoiding biliary fistula) (41).
This preoperative assessment seems particularly helpful in patients
with unconventional resection planes and in those with central
tumors. It allows complicated anatomical LR being adapted to
more number of patients, such as subsegment anatomical LR for
small tumor in highly injured liver and anatomical LR of com-
bined territories for deep centrally located tumor on the border of
territories.
LAPAROSCOPIC LR
Since the first successful report in 1992 (42), laparoscopic LR is
thought to be a less invasive procedure than conventional open
LR for the treatment of hepatic lesions (43). In a comprehensive
meta-analysis study, laparoscopic LR was compared to open in
1,678 patients across 26 studies (44). While it is associated with
longer operating times and no differences in oncological out-
comes, it is advantageous in several aspects. Laparoscopic LR is
associated with reduced blood loss, decreased portal clamp time,
decreases in overall and liver-specific complications, and shorter
post-operative hospital stays. Recent technological development
of devices and accumulation of experiences have facilitated the
expansion of the indication of the procedure (6, 45). Although
common advantages of laparoscopic surgery, such as early recovery
and discharge with smaller post-operative pain and earlier intake,
have also been reported for laparoscopic hepatectomy (46), spe-
cific advantages and the indication of laparoscopic LR have yet to
be well settled.
Even limited LR under open surgery for severe CLD patients
often develops refractory ascites, which leads to fatal complica-
tions (47, 48). Laparoscopic LR may be particularly advantageous
for those patients, given the potential for lower levels of parietal
and hepatic injury and the preservation of venous and lymphatic
collateral circulation, especially for the patients with multicen-
tric/metachronous lesions occurring in chronically injured liver.
The safety and feasibility of the laparoscopic approach and its
short-term benefits for HCC patients with CLD have been demon-
strated by several series. To date, several studies have investi-
gated the major differences between laparoscopic LR and open
LR (49–59). Favorable short-term results, including fewer inci-
dences of ascites and liver failure, and shorter post-operative
hospital stay correlates with the laparoscopic procedure. Tran-
chart et al. reported laparoscopic LR of HCC for selected patients
resulted in better post-operative outcomes without long- and
short-term oncologic consequences (60). Also in our experi-
ence (61), we reported the favorable perioperative course of the
patients with severe CLD (Child B/C and ICG R15 of 40% or
above) who underwent pure laparoscopic LR, which is compara-
ble to that of the patients with mild/moderate CLD (Child A and
ICG R15 of 10.1–27.4%). This study showed that laparoscopic
LR has the advantage of minimal ascites (61) in addition to
usual advantages of laparoscopic surgery, due to the preserva-
tion of venous and lymphatic collateral circulation, which leads
to lower risk of disturbance in water and/or electrolyte bal-
ance and hypoproteinemia that could trigger fatal liver failure.
This feature could be the most remarkable specific advantage
for laparoscopic LR. Patients who undergo LR are exposed to
three different types of stresses: (1) general, whole-body surgi-
cal stress, (2) reduced liver function due to resected liver volume,
and (3) surgery-induced injury for liver parenchyma and envi-
ronment around the liver caused by destruction of the collateral
blood/lymphatic flow by laparotomy plus mobilization of the
liver and parenchymal injury by compression of the liver. Reduc-
tion of the third mentioned stress by laparoscopic LR should
lower the risk for HCC patients with severe CLD. Among these
patients with severe CLD in our series, one underwent living-
related LT 20 months after hepatectomy (28). The procedure could
also be an advantageous option in bridging therapy to LT for
certain HCC patients with severe CLD. Furthermore, our expe-
rience showed laparoscopic LR also results in improved vision
and manipulation in a small operative field under several con-
ditions, such as repeat hepatectomy with adhesions (28) and,
also, some novel approach of LR [for example, caudal approach,
not anterior approach, for oncologically appropriate posterior
sectorectomy and right hepatectomy (62)] is also possible laparo-
scopically. These characteristics of laparoscopic LR may indicate
that it is a superior method when compared to open LR under
certain conditions and its application may lead to expanding
indication of LR.
ADJUVANT AND/OR COMBINED THERAPY FOR LR
Recurrence after LR occurs in up to 80% of patients at 5 years
(63). Two-year cutoff has been raised to distinguish between early
and late recurrence. Two-thirds of the recurrence occurs within
2 years, which is considered as dissemination from the original
tumor (64). The factors related to this recurrence are tumor size,
microvascular invasion, satellite nodules, α-fetoprotein levels, and
non-anatomical resection. Large portion of delayed recurrence
may correspond to “de novo” tumors in the oncogenic CLD liver
(65). Presence of cirrhosis (F4), hepatitis activity, and multinodu-
larity are in the risk factors associated with delayed recurrence,
besides vascular invasion, and moderate or poorly differentiated
HCC (64).
Several strategies have been tested to prevent recurrence, such
as preoperative chemoembolization (66), chemotherapy, inter-
nal radiation (67), adoptive immunotherapy (68), retinoids (69),
or interferon. Three meta-analyses that favored the use of inter-
feron have been published (70, 71), although there are few good-
quality studies. Whether there is definite efficacy of the agent
and, if there is, also whether the effect of interferon works on
early recurrence as an anti-cancerous agent or on delayed recur-
rence through the control of CLD activity are still under discus-
sion. The efficacy of sorafenib in advanced stages has encour-
aged evaluation of this agent at earlier phases of the disease,
and the trials are ongoing. There is no proven neoadjuvant
therapy that can decrease or delay the incidence of intrahep-
atic recurrence after LR (72). Despite the facts that TACE can
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downstage HCC, prospective trials have failed to show any sig-
nificant benefit of this treatment before LR (73, 74). Although
recurrence following LR is associated with a poor outcome in
most cases, there is growing evidence that some patients with
only intrahepatic recurrence will benefit from more aggressive
approaches (75, 76). Multimodality therapy of recurrence, includ-
ing TACE, percutaneous ablative therapy, and re-resection could
result in prolonged survival, with an overall 5-year survival rate of
20% (75).
Vascular invasion of HCC, particularly portal and hepatic
venous tumor thrombus (VTT), is one of the indicators of patient
prognosis and development of tumor thrombi in a major branch
of the veins is a frequent terminal feature of HCC. The prognosis
of such patients is extremely poor, and survival is limited to a few
months after diagnosis (77–79). For these advanced HCCs, con-
ventional therapies like TACE and percutaneous ablative therapy
are not indicated due to lack of efficacy and associated compli-
cations (80, 81). LT is a contra-indication for such cases (80).
Several reports have mentioned the feasibility of LR for patients
with VTT. However, the outcome is unsatisfactory with median
survival of 6–12 months (77, 78, 81, 82), except for the cases with
VTT located in the segmental or sectoral branches (83). Several
approaches have been attempted to improve the surgical results,
including combined radiotherapy and TACE to date with unsat-
isfactory results (84–87). There are recently emerging reports that
the clinical efficiency of IFN-α plus transarterial 5-fluorouracil
(5-FU) combination therapy for advanced HCC with VTT and
intrahepatic metastasis (88–90) and also for resectable HCC as
a post-operative adjuvant (91) and a multimodal treatment (7).
The results show that this combination therapy with LR is a
promising candidate for the treatment of such condition and other
advanced cases. Now, several clinical trials for this combination
therapy are ongoing. We also previously reported the efficacy of S-1
plus cisplatin combination therapy for the patients with advanced
and/or recurrent primary liver carcinomas including HCC (92)
and of TACE using degradable starch microspheres (DSM) in
patients with liver tumors (93). This chemoembolization using
DSM induces only short-term temporary vascular occlusion and
chemotherapeutic agent retention on the site, which is applica-
ble repeatedly in short interval with mild damage on the vessels
and non-cancerous liver tissue (93). The potential candidates of
adjuvant and/or combined therapy for LR should be tested for the
future improvement of prognosis in recurrent and/or advanced
patients.
LIVER RESECTION AND LIVER TRANSPLANTATION
Impairment of liver function and the risk of multicentric carcino-
genesis from chronically injured liver tissue lead to consideration
of LT as the ideal treatment for removal of existing tumors and
injured/preneoplastic underlying liver. Furthermore, it also pre-
vents the development of post-operative complications associated
with portal hypertension and liver failure. LT is not limited by
liver function, and in selected patients with limited tumors, sur-
vival is similar to LT for other indications (94, 95). However, it
became evident that patients with extensive HCC had very poor
outcomes, whereas most patients with small tumor load could be
cured. Thus, there are discussions for the LT in patients with HCC
about the matters, such as the selection of patients in the back-
ground of the organ shortage, control of tumors for patients on
the waiting list (96).
On the waiting list for LT, HCC patients can experience tumor
growth beyond the LT criteria and a high cumulative probability of
drop-out from the waiting list. This probability has been reported
to range between 7 and 11% at 6 months and to be approximately
38% at 12 months after enrollment by two reports at the late 1990s
(97, 98).
Belghiti et al. have demonstrated that surgical resection before
LT (“bridging LR”) does not increase the surgical risk nor impair
survival (99) and stated that resection and transplantation could be
associated rather than considered separately. They mentioned that
resection could be used as a bridge to transplantation, especially
for tumors located in the upper part of the right liver, which can be
easily and completely removed through a transthoracic incision.
Similarly, some superficial tumors that are not easily accessible by
a percutaneous approach could be resected through a laparoscopic
approach.
Several studies have confirmed that LT for recurrence after
LR did not increase the operative risk and offered a chance of
long-term survival when HCC recurrence was limited (99–101).
Initial LR of HCC as primary therapy in patients, who otherwise
could have been transplanted offers good quality of life and is less
demanding than LT. Patients do not need long-term immunosup-
pression; in addition, grafts are saved for the community and can
be transplanted to other patients with no alternative to LT (99,
100, 102). “Salvage transplantation” was first proposed by Majno
et al. (103) for tumor recurrence or deterioration in liver function
of the patients after LR as primary therapy. This concept seems
to be applicable in a significant proportion of patients with long-
term survival similar to that of patients who undergo primary LT
(99–101). Also, histological analysis of specimens from LR, either
Table 1 | Summary of recent advances in liver resection for
hepatocellular carcinoma.
1. Current concept of liver resection for hepatocellular carcinoma
• Most available and efficient treatment for HCC
• Applicable <30% of all HCC patients
• 5 year survival rate after resection is 38–61% depending on the stages
• 80% Of the patients recurred within 5 years after resection
2. Recent advances in liver resection for hepatocellular carcinoma
• 3D CT-assisted preoperative surgical planning
Facilitation for unconventional types of liver resection
• Laparoscopic liver resection
Benefits for the patients with severe CLD with lower morbidity
Benefits for the repeat resection
(Benefits as a bridging therapy for liver transplantation)
• Adjuvant and/or combined therapy with newly developing chemotherapy
(sorafenib, intra-arterial 5-FU plus IFN therapy for HCC with VTT, etc.)
Prospects of expanding indication for advanced tumor
• Current concepts of “bridging LR” and “salvage transplantation”
LR and LT could be associated rather than considered separately
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in “bridging” or “salvage” setting, allows to show pejorative factors
of the tumor, which lead to a valid selection of the subgroup of
patients who could benefit from following LT.
CONCLUSION (TABLE 1)
The association of HCC with CLD is making treatment
complex and challenging. The treatment of HCC must take into
consideration, the severity of CLD, the stage of HCC, and the
clinical condition of the patient.
There are recent advances and prospects in LR for HCC in sev-
eral aspects. Three-dimensional CT imaging assisted preoperative
surgical planning facilitates unconventional types of LR. Emerging
evidences of laparoscopic hepatectomy and prospects for the use
of newly developing chemotherapies as a combined therapy may
lead to expanding indication of LR.
Liver resection and LT could be associated rather than consid-
ered separately with the current concepts of “bridging LR” and
“salvage transplantation.”
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